Arbutus Biopharma Corp (NAS:ABUS)
$ 3.34 -0.29 (-7.99%) Market Cap: 630.31 Mil Enterprise Value: 557.49 Mil PE Ratio: 0 PB Ratio: 5.22 GF Score: 60/100

Arbutus Biopharma Corp at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 30, 2021 / 12:40PM GMT
Release Date Price: $4.29 (+0.47%)
Emily Bodnar
Cantor Fitzgerald - Analyst

Hello, everyone. Thanks for joining us today. My name is Emily Bodnar and I'm an associate here at Cantor Fitzgerald. I'm happy to introduce Bill Collier, who is the President and CEO of Arbutus Biopharma. We will be doing a formal presentation. And with that, I will pass it off to Bill to begin.

Bill Collier
Arbutus Biopharma Corporation - President & CEO

Thank you very much. Good morning and welcome, everybody. Thank you for your interest and your time today. These are our forward-looking statements, and these can be found on our Company website, www.arbutusbio.com. And by way of introduction to Arbutus, I would like to highlight a couple of key points. One is we are a company that is focused on chronic hepatitis B infection. And we are focused on this because it is a significant unmet medical need with a global prevalence probably double that of hepatitis C. So the potential for a very large market.

And our aim is to find a functional

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot